|Anti-β-Gal-hIgG1 (N298A)||Unit size||Cat. code||Docs||Qty||Price|
β-galactosidase antibody - Human IgG1 (N298A)
Monoclonal human IgG1 (N298A) antibody against E. coli β-galactosidase
Anti-β-Gal-hIgG1 (N298A) features the constant region of the human IgG1 (N298A) isotype and the variable region of Mouse IgG2a Control. Mouse IgG2a Control is a mouse IgG2a monoclonal antibody that targets E. coli β-galactosidase (β-Gal). This antibody was generated by DNA immunization with a plasmid expressing the β-Gal gene in Swiss mice.
Anti-β-Gal-hIgG1 (N298A) can be used as an isotype control for human IgG1 antibodies containing the N298A mutation. Antibodies with this mutation contain a modified Fc region designed to limit antibody-dependent cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) [1, 2], as this mutation eliminates their ability to bind to human Fcγ receptors.
Anti-β-Gal-hIgG1 (N298A) was generated by recombinant DNA technology. It has been produced in CHO cells and purified by affinity chromatography with protein G.
- Spigel D. et al., 2013. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) [ASCO abstract 8008]. J Clin Oncol. 31(15)(suppl).
- Herbst RS. et al., 2014. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 515(7528):563-7.
Clonality: Monoclonal antibody
Specificity: E. coli β-galactosidase (β-Gal)
Isotype: Human IgG1 (N298A)
Application: Negative control for human IgG1 antibodies
Source: CHO cells
Purity: Purified by affinity chromatography with protein G
- The absence of binding of Anti-β-Gal-hIgG1 (N298A) to human cell lines has been tested using flow cytometry.
- The absence of endotoxins and other bacterial contaminants has been confirmed using HEK-Blue™ TLR4 and HEK-Blue™ TLR2 cells.
200 µg purified anti-β-Gal-hIgG1 (N298A) antibody, provided azide-free and lyophilizedBack to the top